The management of metastatic renal cell carcinoma (mRCC) has been revolutionized, with targeted therapies (TTs) superseding cytokine therapy (interferon-*α* and interleukin-2). Indeed, because of the number of therapies now available, the identification of prognostic factors has an important role in the clinical management of the advanced disease ([@bib8]; [@bib21]).

Prognostic factors allow a homogeneous stratification of patients in clinical trials, avoiding the identification of any group in which a TT has greater activity, which would constitute a selection bias ([@bib16]).

In the cytokine era, the most commonly used prognostic criteria have been those developed by Motzer, who assessed 670 patients enroled in clinical trials of immunotherapy and chemotherapy at the Memorial Sloan Kettering Cancer Centre ([@bib15]). The multivariate analysis has revealed that haemoglobin, serum lactate dehydrogenase, corrected serum calcium level, nephrectomy status and Karnofsky Performance Status (PS) were independent risk factors for prediction of survival.

Using a combination of these factors, patients were stratified as being of favourable, intermediate or poor risk, with mean survival times of 20, 10 and 4 months, respectively.

The predictive role of this model has been successfully validated, with some modifications, by a retrospective analysis that included 353 patients with mRCC at the Cleveland Clinic ([@bib11]).

This study confirms the prognostic role for all factors identified by Motzer, with the exclusion of PS, and reveals two more prognostic factors: prior radiotherapy and number of sites of metastases.Reported median survival times were 26.0, 14.4 and 7.3 months, respectively ([@bib11]).

Despite their validation only in patients treated with cytokines, these models have also frequently been used to assess the risk of death in patients treated with TTs in major phase II--III trials in mRCC.

Choueiri *et al* (2007) proposed a new classification for patients receiving antiangiogenic agents, confirming the independent predictive role for Eastern Cooperative Oncology Group (ECOG) PS, time from diagnosis to current treatment and abnormal baseline-corrected serum calcium and revealing higher platelet and absolute neutrophil counts as two new prognostic factors.

Similar to the previous classification, patients were grouped according to the number of prognostic factors (⩽1, 2 or ⩾3 prognostic factors) and a difference in median overall survival (mOS) was found (20.1, 13 and 3.9 months, respectively) ([@bib2]). The largest analysis in patients with mRCC treated with TT was performed by [@bib8]. In this study, the role of low haemoglobin, high serum-corrected calcium, Karnofsky PS \<80 and time from diagnosis to therapy initiation \<1 year were confirmed as independent predictors of shorter survival. Furthermore the absolute neutrophil and platelet counts greater than the upper limit of normal were also considered prognostic factors.

The mOS was not reached in the favourable-risk group, but was 27.0 and 8.8 months in the intermediate-risk and poor-risk groups, respectively ([@bib8]).

This study did not report a difference in outcomes with the use of antiangiogenic therapy as first- or second-line therapy, and confirms the poor prognosis for non-clear-cell histology, although this factor was not included in the final model ([@bib8]).

Recently [@bib10] reported the results from the International Kidney Cancer Working Group, which validated the role of prognostic factors for survival in patients with mRCC. From a comprehensive international database, data for 3748 patients with mRCC were analysed to identify independent predictors of survival.Nine clinical factors were considered in this analysis; treatment, PS, number of metastatic sites, time from diagnosis to treatment, pretreatment haemoglobin, white blood count, lactate dehydrogenase, alkaline phosphatase and serum calcium.These factors formed three risk groups using the 25th and 75th percentiles of the resulting prognostic index.This model showed good concordance among the 645 patients treated with tyrosine kinase inhibitors (*C* statistic=0.741; 95% CI 0.714, 0.768).

All these studies show that TTs have approximately doubled the median survival in patients with mRCC compared with the data reported by Motzer in the cytokine era (22 *vs* 10 months) and that the efficacy of sequential TTs is independent of the treatment sequence used.

Some questions remain unanswered; no factor has been reported as prognostic for patients receiving mammalian target of rapamycin inhibitors, and the role of nephrectomy is still undefined as a prognostic factor in patients with mRCC receiving TTs.

A series of consecutive patients with mRCC and treated with TTs at IRCCS Istituto Nazionale dei Tumori in Milan were examined to evaluate the role of several prognostic factors. The preliminary results of this retrospective study have been published previously ([@bib19]).

Materials and methods
=====================

Patients
--------

Consecutive patients with mRCC, aged ⩾18 years and with an ECOG PS of 0, 1 or 2, who were treated with one or more TTs, were eligible for inclusion in this retrospective study. Baseline characteristics and outcomes of patients were collected from the database of Istituto Nazionale dei Tumori, Milan, Italy.

A number of patients enrolled in this study had previously taken part in a range of prospective trials including TARGET ([@bib5]), the EU-ARCCS ([@bib1]), RECORD-1 ([@bib14]), AXIS ([@bib20]), AVOREN ([@bib6]) and ROSORC ([@bib18]).

The study was conducted in accordance with the International Conference on Harmonization for Good Clinical Practice ([@bib4]), and it was approved by the local ethics committee and institutional review board.

Treatment and study assessments
-------------------------------

All patients included in the final database received TT as first-line treatment, or subsequent cytokine therapy. The TTs were: sorafenib 400 mg twice daily orally, sunitinib 50 mg daily (4 weeks on, 2 weeks off) orally, bevacizumab 10 mg/kg intravenously every 2 weeks in combination with subcutaneous interferon-*α*, everolimus 10 mg daily orally, temsirolimus 25 mg intravenously weekly or axitinib 10 mg daily orally. Patients received systemic therapy until disease progression or the presence of serious adverse events.

Statistical analyses
--------------------

For the description of clinical, pathological and treatment characteristics of the patients, categorical variables were described using absolute and relative frequencies; continuous variables were described using the median as a measure of central tendency and the range as a measure of dispersion. *χ*^2^ test for trend was performed in order to determine whether Motzer classification was a significant predictor of the number of therapy cycles. Overall survival was defined as the time from initiation of treatment with TTs to the date of death or last follow-up. The Kaplan--Meier method was used to estimate survival probabilities; the inverse Kaplan--Meier method was used to estimate the median follow-up; the log-rank test was used to detect a statistically significant difference in survival; the Cox regression model was used to estimate hazard ratios (HRs) and to identify independent prognostic factors by using a backward selection strategy; all the baseline characteristics were introduced in the backward selection algorithm. All statistical tests were two-sided and a *P*-value \<0.05 was considered statistically significant; the same threshold was used as the criterion for retaining variables in the backward selection algorithm.. Statistical analysis was performed using SAS software, version 9.2 (SAS Institute, Cary, NC, USA); the statistical package Stata, version 12.0 (StataCorp, College Station, TX, USA) was used for Kaplan--Meier plots.

Results
=======

Patients and treatments
-----------------------

A total of 336 patients with mRCC were treated with TTs at the Istituto Nazionale dei Tumori in Milan between January 2004 and October 2011 ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}, flow chart). Patient characteristics at baseline are shown in [Table 1](#tbl1){ref-type="table"}. For the definition of Motzer risk groups the following factors were considered: ECOG PS status as 0 *vs* 1 and above, nephrectomy status, HgB, LDH and corrected calcium. Similar to the previous classification, patients were grouped according to the number of prognostic factors (0, 1--2 or ⩾3) in low, intermediate and poor risk, respectively.

According to the Motzer classification 108 (32%) patients were low risk, 159 (48%) intermediate and 66 (20%) poor risk

Nine patients were excluded from survival analysis: seven patients with Bellini duct carcinoma characterised by an aggressive course and two patients because survival outcome was not available. Patients were followed for a median of 43 months (range 0.5--88.1 months). Median overall survival was 24 months (95% CI: 20.0, 27.0) and the 5-year overall survival rate was 24.6% (95% CI: 18.7, 30.8) ([Figure 1](#fig1){ref-type="fig"}). Overall 199 (57%) patients died.

One hundred and sixty-seven (49.7%) patients received only one TT, 116 (34.5%) received a second-line TT, 42 (12.5%) a thirdline and 11 (3.3%) patients received a fourth-line TT; overall 245 (72.9%) patients received sorafenib, 212 (63.1%) sunitinib, 33 (9.8%) bevacizumab and 73 (21.7%) another/other TT(s).

The majority of patients (*n*=295, 87.8%) received sorafenib or sunitinib as the first TT; of these, 205 (61.0%) patients received sorafenib; of the remaining patients 28 (8.3%) received bevacizumab, 8 (2.4%) temsirolimus, 3 (0.9%) bevacizumab in combination with everolimus, 1 (0.3%) bevacizumab in combination with erlotinib and, 1 (0.3%) pazopanib.With regard to second-line treatment, sorafenib was followed by sunitinib in 101 out of 111 (91.0%) patients and sunitinib was followed by sorafenib in 19 out of 29 (65.5%) patients.

Treatment outcomes
------------------

Regarding the association between the Motzer classification and the number of therapy cycles, a negative trend was detected (*χ*^2^=10.718, *P*=0.001); the median number of treatments was two in the low and intermediate risk groups, and one in the high-risk group. Regarding patients who received at least a second-line therapy, there was no significant correlation between the sequence of TT and survival (HR~sunitinib→sorafenib/sorafenib→sunitinib~=1.16; 95% CI: 0.57--2.33; HR~Other/sorafenib→sunitinib~= 1.21; 95% CI: 0.78--1.88; *P*=0.674) as presented in [Table 2](#tbl2){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}.

Prognostic factors
------------------

At the univariate level, Motzer risk class, ECOG PS, nephrectomy, Fuhrman grade, number of sites of disease and previous cytokine treatment were predictive factors for survival, but there were no differences based on tumour histology, age, sex or treatment sequence ([Table 2](#tbl2){ref-type="table"}).

Median survival and 5-year overall survival rate according to the Motzer criteria were 44 months (95% CI 33.0, 63.1) and 40.0% (95% CI 28.4, 51.3) in low-risk patients, 22 months (95% CI 17.0, 27.0) and 21.4% (95% CI 12.8, 31.4) in intermediate-risk patients and 9 months (95% CI 7.0, 11.0) and 0% in patients considered high risk (*P*\<0.001) ([Figure 3A](#fig3){ref-type="fig"}).

The multivariate analysis identified the following independent prognostic factors: Motzer score (HR~intermediate_vs_low~=2.39; 95% CI 1.67, 3.41; HR~high_vs_low~=7.41; 95% CI 4.89, 11.24; *P*\<.001); Fuhrman grade (HR~3--4_vs_1--2~=1.59; 95% CI 1.19, 2.12; *P*=0.002) and previous cytokines (HR~yes_vs_no~=1.50; 95% CI 1.13, 2.00; *P*=0.005). Adjusting for all baseline characteristics statistically associated to overall survival nephrectomy confirmed its prognostic role (HR=0.52; 95% CI:0.32--0.82; *P*=0.006) ([Figure 3B--D](#fig3){ref-type="fig"}) ([Supplementary Tables 1 and 2](#sup1){ref-type="supplementary-material"}).

Discussion
==========

The high level of molecular and pathological heterogeneity in RCC contributes to the varying prognoses and outcomes that characterise this disease ([@bib9]). A more detailed knowledge and understanding of the individual risk factors that predict patient\'s responses would be beneficial not only for individual patient management and treatment choices, but also for clinical trial design to ensure better definition of patient risk groups ([@bib9]; [@bib21]).

Several prognostic factors have been established for the outcomes of patients with advanced RCC. The majority of the research on this topic applies to the treatment with cytokines, interferon-*α* and interleukin-2 ([@bib15], [@bib16], [@bib13]; [@bib11]; [@bib2]). With the subsequent introduction of novel targeted anticancer therapies, the models of prognostic factors are required to be revalidated for the new treatments.

With regard to the new therapies for patients with mRCC, [@bib10] validated nine prognostic factors and developed a prognostic model for survival, including three risk groups (favourable, intermediate and poor) characterised by 26.9, 11.5 and 4.2 months of overall survival, respectively. This study was the largest of its kind, validating the role of prognostic factors in a population receiving TTs.

For patients receiving TTs (mostly sorafenib, sunitinib and bevacizumab), our study highlighted the prognostic role of the Motzer classification according to the uni- and multivariate analyses. Similar to that previously reported by [@bib8], the mOS of patients described in this report was notably increased compared with that demonstrated by [@bib15].

The increased survival reported for patients with mRCC may well be associated with the improvement of diagnostic and surgical procedures and best supportive care, but it is also due to the greater efficacy of the new systemic therapies. Moreover, this survival improvement has been reported for all risk groups; the mOS was 43, 21 and 8 months for favourable-, intermediate- and poor-risk groups, respectively, which is double the overall survival reported previously for patients treated with cytokines (20, 10 and 4 months, respectively) ([@bib13]).

There was no survival difference for different treatment sequences or types of TTs received, as discussed in a previous study ([@bib19], [@bib18]).

Among the parameters of the Motzer risk classification, the univariate analysis showed nephrectomy as an independent variable prognostic factor for survival in patients treated with TTs. The prognostic role of cytoreductive nephrectomy (CN) in patients affected by mRCC was first reported by [@bib15], and subsequently confirmed by two prospective studies, which showed a longer overall survival with CN combined with cytokine therapy than with systemic treatments alone ([@bib7] and [@bib12]).

Recently, the role of CN has been questioned, considering the high-response rate and the improvement of survival achieved with TTs ([@bib22]). Although the prognostic role of previous nephrectomy has been recently reported in patients with mRCC treated with TTs ([@bib3]; [@bib23]), the analysis of prognostic factors for patients enrolled in a phase III trial of sunitinib failed to find it ([@bib17]). Furthermore, the role of CN on tumour control by TTs is also disputed, as two large retrospective analyses report conflicting results ([@bib3]; [@bib17]).

Our study, larger than that published by [@bib23] and similar to that of [@bib3], regarding the number of patients and the type of treatments, reports a survival benefit and the independent prognostic role of CN in patients with mRCC treated with TTs.

The current prognostic role of CN in patients with mRCC treated with TTs is therefore not yet clearly defined and probably only ongoing phase III trials will in time answer this question ([@bib22]). Proof of that considering only our retrospective analysis patients who did not receive a CN often had bad clinical conditions or multiple sites of disease and bulky disease. Therefore, this last population had additional unfavourable factors that could explain the worse prognosis of the disease.

Additionally the uni- and multivariate analyses showed the Fuhrman grade and previous therapy with cytokines as independent factors of clinical outcome. In our experience, patients treated with cytokines received too-late TTs for advanced disease, and often only one antiangiogenic treatment, which could, in our opinion, justify the worse prognosis of this subgroup of population.

Fuhrman grade is well-recognised to be an independent prognostic factor for recurrence in patients nephrectomised.

Our experience disclosed that also in advanced disease treated with TTs, Fuhrman grade could have a role as independent prognostic factor for outcome (see [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}).

Additionally, some factors, such as number of sites of disease and number of TTs, were confirmed as prognostic factors only in the univariate analysis, suggesting that they may be less relevant ([Table 2](#tbl2){ref-type="table"}).

With this study being designed to elucidate prognostic factors in mRCC, its retrospective design constitutes a distinct limitation on the interpretation of results. Also not considered in this study was the heterogeneity, which usually characterises mRCC and any biological parameters.

In conclusion, the Motzer criteria were validated as prognostic factors for survival in patients with mRCC receiving TTs. Additionally, Fuhrman grade and use of previous cytokines were independent prognostic factors of clinical outcome.

These data may be useful for improved patient management and treatment decision making, as well as stratification of patient groups in clinical trials, for better interpretation and application of outcomes of studies of TTs in patients with mRCC.
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###### Baseline characteristics of the patient population with metastatic renal cell carcinoma treated with targeted therapies

  **Characteristics**             ***N***    **%**
  ---------------------------- ------------- -------
  Median age, years (range)     62 (25--82)   
                                              
  *Sex*                                      
   Male                             248      73.8
   Female                           88       26.2
                                              
  *ECOG PS*                                  
   0                                186      55.4
   1                                131      39.0
   2                                19       5.7
                                              
  *Histology*                                
   Clear-cell                       291      86.9
   Non-clear cell                   45       13.1
    Papillary                       29       65.9
    Bellini                          7       15.9
    Chromophobe                      7       15.9
    Oncocytoma                       1       2.3
   Missing data                      1       0.3
                                              
  *Previous nephrectomy*                     
   Yes                              293      87.2
   No                               43       12.8
                                              
  *Fuhrman grade*                            
   1                                15       5.1
   2                                99       33.8
   3                                131      44.7
   4                                48       16.4
   Missing data                     43       12.8
                                              
  *Motzer risk class*                        
   Low risk                         108      32.4
   Intermediate risk                159      47.7
   High risk                        66       19.8
   Missing data                      3       0.9
                                              
  *Number of disease sites*                  
   1                                126      37.8
   2                                117      35.1
   3                                67       20.1
   4                                18       5.4
   5                                 4       1.2
   6                                 1       0.3
   Missing data                      3       0.9
                                              
  *Sites of disease (n=659)*                 
   Bone                             94       28.2
   Brain                            16       4.8
   Liver                            62       18.6
   Lung                             221      66.4
   Lymph nodes                      127      38.1
   Pancreas                         17       5.1
   Thyroid                           5       1.5
   Other                            117      35.1
   Missing data                      3       0.9

###### Univariate overall survival analysis for patients with metastatic renal cell carcinoma treated with targeted therapies

                                                                                **Hazard ratio**                                  
  ------------------------------------------------ -------------------------- -------------------- ------------- ---------------- -------------------
  **Variable**                                           **Categories**        **Point estimate**   **95% CI**    ***χ***^**2**^   ***P*****-value**
  *Baseline characteristics*                                                                                                      
   Age[a](#t2-fn2){ref-type="fn"}                             ---                     1.00          0.89, 1.13        0.002              0.964
                                                                                                                                            
   Sex                                                       Female                    1                              0.153              0.695
                                                              Male                    1.07          0.77, 1.48                              
                                                                                                                                            
   ECOG PS                                                     0                       1                              26.806            \<0.001
                                                               1                      1.84          1.37, 2.46                              
                                                               2                      3.29          1.86, 5.81                              
                                                                                                                                            
   Histology[b](#t2-fn3){ref-type="fn"}                    Clear-cell                  1                                                    
                                                           Papillary                  1.38          0.88, 2.18        2.012              0.366
                                                             Other                    1.13          0.50, 2.54                              
                                                         Non clear-cell               1.32          0.88, 1.98        1.769              0.183
                                                                                                                                            
   Nephrectomy                                                 No                      1                              8.556              0.003
                                                              Yes                     0.52          0.34, 0.81                              
                                                                                                                                            
   Previous cytokines                                          No                      1                              6.239              0.012
                                                              Yes                     1.43          1.08, 1.89                              
   Fuhrman grade                                              1--2                     1                              11.829            \<.001
                                                              3--4                    1.64          1.24, 2.18                              
                                                                                                                                            
   Motzer risk groups                                         Low                      1                              77.636            \<0.001
                                                          Intermediate                2.05          1.45, 2.91                              
                                                              High                    7.27          4.80, 11.02                             
                                                                                                                                            
   No. of disease sites                                       0--1                     1                              19.299            \<0.001
                                                               2                      1.86          1.32, 2.62                              
                                                              \>2                     2.17          1.52, 3.09                              
                                                                                                                                            
  *Treatment*                                                                                                                     
   First-line                                                  SO                      1                              8.695              0.013
                                                               SU                     0.53          0.35, 0.81                              
                                                    Other targeted therapies          0.82          0.52, 1.29                              
                                                                                                                                            
   Sequential therapy[c](#t2-fn4){ref-type="fn"}             SO→SU                     1                              0.788              0.674
                                                             SU→SO                    1.16          0.57, 2.33                              
                                                        Other sequences               1.21          0.78, 1.88                              

Abbreviations: CI=confidence interval; ECOG PS=Eastern Cooperative Oncology Group Performance Status; SO=sorafenib; SU=sunitinib.

Age in 10-year increments.

Two main histological classifications included.

In patients receiving a second targeted therapy.

###### Multivariate overall survival analysis for patients with metastatic renal cell carcinoma treated with targeted therapies

                                             **Hazard ratio**                          
  --------------------------- -------------- ------------------ ------------- -------- ---------
  Previous cytokine therapy         No       1                                7.909    0.005
                                   Yes       1.50               1.131, 2.00             
                                                                                        
  Fuhrman grade                    1--2      1                                10.008   0.002
                                   3--4      1.59               1.193, 2.12             
                                                                                        
  Motzer risk groups               Low       1                                89.712   \<0.001
                               Intermediate  2.39               1.67, 3.41              
                                   High      7.41               4.89, 11.24             

Abbreviation: CI=confidence interval.
